AbbVie Inc (ABBV.xnys) is a biopharmaceutical company headquartered in North Chicago, Illinois, America. AbbVie, after the separation from Abbott Laboratories, started operating as a research-based pharmaceutical manufacturer to allow markets to value the two businesses separately. The company is committed to product development in the cystic fibrosis disease area and plans to reduce emissions by 25 per cent by 2025. Abbvie employs 47,000 people in 170 countries across the globe. AbbVie Inc stock (ABBV.xnys) is listed on the New York Stock Exchange (NYSE) and had a $45.80B (USD) market capitalisation as of January 2022. The company announced the acquisition of Soliton Inc at the beginning of 2022 in order to include a proven treatment for the appearance of cellulite. AbbVie has also got approval from the Food and Drug Administration (FDA) for the RINVOQ medicine to treat adults with active psoriatic arthritis and the VUITY medicine, which is the first and only eye drop to treat presbyopia. The second one is a common and progressive eye condition that affects 128M Americans, and its treatment is now available by prescription in pharmacies nationwide.
AbbVie Inc (ABBV)
Get AbbVie Inc (ABBV) share price insights and news for better trading decisions. Stay informed with FP Markets Greece.